Diagnostics and Therapeutics for Selective Targeting of Early Toxic Oligomers
Time: 10:00 am
day: Blood-Based Biomarker Focus Day
Details:
- Highly specific and sensitive plasma Soluble Oligomer Binding Assay (SOBA) with FDA breakthrough designation for AD
- Soluble Oligomer Binding Inhibitor (SOBIN) for neutralization of toxic oligomers and their effects in vivo
- SOBA test applicable to other amyloid diseases, including PD
